ArticleCancer discovery2020
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Trial
- Sensitivity to ATR-CHK1 pathway inhibition in MDS/AML is enhanced by SRSF2 mutations and reduced by RUNX1 loss.Leukemia · 2026Article
- Reduced PRC2 function causes asparaginase resistance in T-ALL by decreasing WNT pathway activity.Blood advances · 2026Article
- Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas.The Journal of clinical investigation · 2025Article
- Cancer Vulnerabilities Through Targeting the ATR/Chk1 and ATM/Chk2 Axes in the Context of DNA Damage.Cells · 2025Review
- Native stem cell transcriptional circuits define cardinal features of high-risk leukemia.The Journal of experimental medicine · 2025Article
- 3D chromatin hubs as regulatory units of identity and survival in human acute leukemia.Molecular cell · 2025Article
- Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes.Nature communications · 2024Article
- Article
- Key candidate genes and pathways in T lymphoblastic leukemia/lymphoma identified by bioinformatics and serological analyses.Frontiers in immunology · 2024Article
- TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia.Leukemia · 2023Article
- Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.Breast cancer research : BCR · 2022Article
- Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL.Blood · 2022Article
- DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges.Frontiers in pharmacology · 2022Review
- Cell cycle control in cancer.Nature reviews. Molecular cell biology · 2022Review
- Predictive biomarkers and potential drug combinations of epi-drugs in cancer therapy.Clinical epigenetics · 2021Review
- Utilization of CRISPR-Mediated Tools for Studying Functional Genomics in Hematological Malignancies: An Overview on the Current Perspectives, Challenges, and Clinical Implications.Frontiers in genetics · 2021Review
- Pathogenic Impacts of Dysregulated Polycomb Repressive Complex Function in Hematological Malignancies.International journal of molecular sciences · 2020Review
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
17 authors at 3 institutions in 1 country.
Theresa E LeónDepartment of Haematology, UCL Cancer Institute, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0002-0958-5995
Tanya Rapoz-D'SilvaDepartment of Haematology, UCL Cancer Institute, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0001-7194-3522
Cosetta BertoliMRC Laboratory for Molecular Cell Biology, University College London, London, United Kingdom.
Sunniyat RahmanDepartment of Haematology, UCL Cancer Institute, University College London, London, United Kingdom.
Michael MagnussenDepartment of Haematology, UCL Cancer Institute, University College London, London, United Kingdom.
Brian PhilipDepartment of Haematology, UCL Cancer Institute, University College London, London, United Kingdom.
Nadine FarahDepartment of Haematology, UCL Cancer Institute, University College London, London, United Kingdom.
Simon E RichardsonDepartment of Haematology, UCL Cancer Institute, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0003-4343-4784
Sara AhrabiDepartment of Haematology, UCL Cancer Institute, University College London, London, United Kingdom.
José Afonso Guerra-AssunçãoBill Lyons Informatics Centre, UCL Cancer Institute, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0001-6593-403X
Rajeev GuptaStem Cell Laboratory, UCL Cancer Institute, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0001-9573-0505
Elisabeth P NachevaHealth Service Laboratories LLP, UCL Cancer Institute, London, United Kingdom.
Stephen HendersonBill Lyons Informatics Centre, UCL Cancer Institute, University College London, London, United Kingdom.
Javier HerreroBill Lyons Informatics Centre, UCL Cancer Institute, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0001-7313-717X
David C LinchDepartment of Haematology, UCL Cancer Institute, University College London, London, United Kingdom.
Robertus A M de BruinMRC Laboratory for Molecular Cell Biology, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0001-9957-1409
Marc R MansourDepartment of Haematology, UCL Cancer Institute, University College London, London, United Kingdom. m.mansour@ucl.ac.uk.
CRUK Lung Cancer Centre of Excellence · GBMRC Laboratory for Molecular Cell Biology · GBCancer Research UK · GB
Funding
Cancer Research UK 20147Cancer Research UK 26238
Abstract
Loss-of-function mutations of
Indexed as
Cell ProliferationCheckpoint Kinase 1Enhancer of Zeste Homolog 2 ProteinHumansMutationPrecursor T-Cell Lymphoblastic Leukemia-LymphomaCheckpoint Kinase 1CHEK1 protein, humanEnhancer of Zeste Homolog 2 ProteinEZH2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.